| 000 | 01861 a2200505 4500 | ||
|---|---|---|---|
| 005 | 20250516101659.0 | ||
| 264 | 0 | _c20121221 | |
| 008 | 201212s 0 0 eng d | ||
| 022 | _a1521-0111 | ||
| 024 | 7 |
_a10.1124/mol.112.078709 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aDaskalopoulos, Evangelos P | |
| 245 | 0 | 0 |
_aDâ‚‚-dopaminergic receptor-linked pathways: critical regulators of CYP3A, CYP2C, and CYP2D. _h[electronic resource] |
| 260 |
_bMolecular pharmacology _cOct 2012 |
||
| 300 |
_a668-78 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aAntipsychotic Agents _xadverse effects |
| 650 | 0 | 4 |
_aCytochrome P-450 CYP3A _xmetabolism |
| 650 | 0 | 4 |
_aCytochrome P-450 Enzyme System _xmetabolism |
| 650 | 0 | 4 | _aDopamine D2 Receptor Antagonists |
| 650 | 0 | 4 |
_aEthanolamines _xmetabolism |
| 650 | 0 | 4 |
_aForkhead Transcription Factors _xphysiology |
| 650 | 0 | 4 | _aGene Expression Regulation |
| 650 | 0 | 4 |
_aHepatocytes _xdrug effects |
| 650 | 0 | 4 |
_aHormones _xblood |
| 650 | 0 | 4 | _aIn Vitro Techniques |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aMicrosomes, Liver _xdrug effects |
| 650 | 0 | 4 |
_aNerve Tissue Proteins _xphysiology |
| 650 | 0 | 4 |
_aPhosphatidylinositol 3-Kinases _xphysiology |
| 650 | 0 | 4 | _aPhosphorylation |
| 650 | 0 | 4 |
_aProto-Oncogene Proteins c-akt _xphysiology |
| 650 | 0 | 4 | _aRats |
| 650 | 0 | 4 |
_aReceptors, Dopamine D2 _xphysiology |
| 650 | 0 | 4 |
_aSTAT5 Transcription Factor _xmetabolism |
| 650 | 0 | 4 | _aSignal Transduction |
| 650 | 0 | 4 |
_aSulpiride _xadverse effects |
| 700 | 1 | _aLang, Matti A | |
| 700 | 1 | _aMarselos, Marios | |
| 700 | 1 | _aMalliou, Foteini | |
| 700 | 1 | _aKonstandi, Maria | |
| 773 | 0 |
_tMolecular pharmacology _gvol. 82 _gno. 4 _gp. 668-78 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1124/mol.112.078709 _zAvailable from publisher's website |
| 999 |
_c21926278 _d21926278 |
||